Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Mini-Catalytically Inactive Cas13X-Derived RNA Base Editing of β-Catenin Attenuates Pulmonary Damage in a Murine Acute Lung Injury Model.

Wenyi Liu | Wanda Bi | Saiying Hou | Juan Du | Ling Zeng | Anqiang Zhang | Huacai Zhang | Dalin Wen | Qingli Cai | Chu Gao | Ping Lin | Min Wu | Li Li | Jianxin Jiang
MedComm | 2026

Acute lung injury (ALI) is characterized by a considerable mortality rate and currently lacks viable therapeutic strategies. Alveolar type II epithelial cells (AT2 cells) play a critical role in lung injury repair, potentially through activation of the Wnt/β-catenin signaling cascade, which may enhance regenerative ability of lung tissue. In this study, we developed a mini-catalytically inactive Cas13X (mini dCas13X)-based adenosine-to-inosine (A-to-I) RNA editing approach, designated as β-catenin T41 editing to treat alveolar type 2 cells (CARTEL), with the objective of alleviating lung damage in ALI. We found that CARTEL proficiently performed base editing on β-catenin, achieving a high A-to-I conversion rate with minimal off-target effects. Moreover, CARTEL significantly inhibited the degradation of β-catenin, amplified Wnt/β-catenin signaling activation and facilitated cellular proliferation. In a murine model of lipopolysaccharide (LPS)-induced ALI, a single adeno-associated virus (AAV)-mediated administration of CARTEL effectively and primarily transduced AT2 cells, resulting in attenuated lung injury, enhanced AT2 cell proliferation, and improved pulmonary function, with no detected long-term risks. Collectively, these findings revealed that CARTEL-mediated RNA editing represents a promising therapeutic strategy to counteract lung injury occurring in diverse settings.

Pubmed ID: 41930349

Additional research tools detected in this publication

None found

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.